-
1 Comment
Hana Pharm Co., Ltd is currently in a long term downtrend where the price is trading 7.0% below its 200 day moving average.
From a valuation standpoint, the stock is 74.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.2.
Hana Pharm Co., Ltd's total revenue rose by 10.7% to $49B since the same quarter in the previous year.
Its net income has dropped by 160.8% to $-4B since the same quarter in the previous year.
Finally, its free cash flow fell by 223.5% to $-6B since the same quarter in the previous year.
Based on the above factors, Hana Pharm Co., Ltd gets an overall score of 2/5.
| Exchange | KO |
|---|---|
| CurrencyCode | KRW |
| ISIN | KR7293480000 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 198B |
|---|---|
| Beta | 0.47 |
| PE Ratio | None |
| Target Price | 20000 |
| Dividend Yield | 3.8% |
Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally. It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as well as analgesics, antipyretics, and anti-inflammatory drugs. The company was founded in 1958 and is headquartered in Seoul, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 293480.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
